MetaCap

Collegium Pharmaceutical (COLL) vs Syndax Pharmaceuticals (SNDX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Collegium Pharmaceutical (COLL) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, losing 45.2% versus a loss of 50.0%. Over five years, COLL leads with a +37.7% price change compared with -47.1% for SNDX. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $768.2 million), about 1.0 times the size.

Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus -165.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COLL-45.24%SNDX-50.00%
+49%-4%-57%
Nov 21, 20251 yearNov 20, 2026
COLL+31.14%SNDX-50.90%
+175%+57%-62%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COLL versus SNDX key metrics
MetricCOLLSNDX
Share price$24.72$8.72
Market cap$768.18M$785.05M
1-day change-1.94%-4.49%
YTD return-46.61%-58.50%
1-year return-45.24%-50.00%
5-year return+37.72%-47.09%
P/E ratio (TTM)22.68—
Forward P/E3.49—
EPS (TTM)$1.09$-2.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$780.57M$172.35M
Revenue growth (YoY)+23.62%+627.84%
Net income (latest FY)$62.87M$-285.42M
Gross margin59.35%—
Operating margin23.01%-158.45%
Net margin8.05%-165.60%
52-week high$50.79$25.59
52-week low$21.43$8.41
Distance from 52-week high-51.33%-65.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+77.99%+306.54%
Average volume754.45K2.63M
Shares outstanding31.08M90.03M
Employees423298
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
  • Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs +23.62%).

About Collegium Pharmaceutical

COLL stock →

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees

About Syndax Pharmaceuticals

SNDX stock →

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees

COLL vs SNDX FAQ

Which is bigger, Collegium Pharmaceutical or Syndax Pharmaceuticals?

Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $768.18M for Collegium Pharmaceutical (COLL).

Which stock has performed better over the past year, COLL or SNDX?

COLL returned -45.24% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.

Are Collegium Pharmaceutical and Syndax Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons